Bcma antigen binding proteins
US-2017165373-A1 · Jun 15, 2017 · US
Binding molecules for BCMA and CD3
US12281176B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12281176-B2 |
| Application number | US-202117336152-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jun 1, 2021 |
| Priority date | Nov 15, 2011 |
| Publication date | Apr 22, 2025 |
| Grant date | Apr 22, 2025 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to a binding molecule which is at least bispecific comprising a first and a second binding domain, wherein the first binding domain is capable of binding to epitope cluster 3 of BCMA, and the second binding domain is capable of binding to the T cell CD3 receptor complex. Moreover, the invention provides a nucleic acid sequence encoding the binding molecule, a vector comprising said nucleic acid sequence and a host cell transformed or transfected with said vector. Furthermore, the invention provides a process for the production of the binding molecule of the invention, a medical use of said binding molecule and a kit comprising said binding molecule.
First claim
Opening claim text (preview).
The invention claimed is: 1. An antibody comprising: a binding domain that binds to human CD3; and further a polypeptide comprising the amino acid sequence of SEQ ID NO: 737 with 0, 1, 2, 3, 4, 5, or 6 amino acid substitutions and 0, 1, or 2 amino acid insertions or deletions to SEQ ID NOs: 731, 732 and/or 733 contained within SEQ ID NO: 737, and 0, 1, 2, 3, 4, 5, 6, 7, 8, or 9 amino acid substitutions and 0, 1, 2, 3 or 4 amino acid insertions or deletions to the remainder of SEQ ID NO: 737. 2. The antibody of claim 1 , wherein the antibody is human or humanized. 3. The antibody of claim 1 , further comprising an IgG framework. 4. The antibody of claim 1 , further comprising an Fc constant domain. 5. The antibody of claim 1 , wherein every amino acid substitution is a naturally occurring amino acid. 6. The antibody of claim 1 , wherein the binding domain that binds to human CD3 is linked to the polypeptide via at least one disulfide bond. 7. The antibody of claim 1 , wherein the antibody is human or humanized, and further comprises an Fc constant domain.
Assignees
Inventors
Classifications
against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154 (against NGF C07K16/22, against TNF C07K16/241) · CPC title
humoral response · CPC title
Vertebrate antigens (from snakes A61K39/38) · CPC title
against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95 · CPC title
Stability, e.g. half-life, pH, temperature or enzyme-resistance · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US12281176B2 cover?
- The present invention relates to a binding molecule which is at least bispecific comprising a first and a second binding domain, wherein the first binding domain is capable of binding to epitope cluster 3 of BCMA, and the second binding domain is capable of binding to the T cell CD3 receptor complex. Moreover, the invention provides a nucleic acid sequence encoding the binding molecule, a vecto…
- Who is the assignee on this patent?
- Amgen Inc, Amgen Res Munich Gmbh
- What technology area does this patent fall under?
- Primary CPC classification C07K16/2809. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Apr 22 2025 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 12 related publications on this page (citations in our corpus or others sharing the same primary CPC).